← Eichor
Condition: Neurofibroma Plexiform Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neurofibroma Plexiform

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform
Phase 3 · 29 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07407803PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase 2 · 1 location(s) · Shanghai Kechow Pharma, Inc. · NCT05331105A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Phase 2 · 14 location(s) · Healx Limited · NCT06541847Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neu
NA · 1 location(s) · Centre Leon Berard · NCT05199376NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272Real-World Treatment Study of Koselugo (Selumetinib)
Phase N/A · 12 location(s) · AstraZeneca · NCT06360406Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractor
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT02390752Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06222203Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and
Phase N/A · 6 location(s) · National Cancer Institute (NCI) · NCT02544022Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Phase 2 · 15 location(s) · University of Alabama at Birmingham · NCT06188741A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillome
NA · 2 location(s) · National Cancer Institute (NCI) · NCT06507748Neurofibromatosis Type 1 Tumor Early Detection Study
Phase N/A · 1 location(s) · David Miller · NCT06515860
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.